The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...